Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E16.04 EPS (ttm)10.26 Insider Own0.10% Shs Outstand736.00M Perf Week2.08%
Market Cap121.15B Forward P/E12.92 EPS next Y12.74 Insider Trans0.00% Shs Float734.84M Perf Month-0.18%
Income7.72B PEG2.47 EPS next Q3.00 Inst Own80.60% Short Float1.20% Perf Quarter7.56%
Sales22.99B P/S5.27 EPS this Y13.10% Inst Trans0.03% Short Ratio2.33 Perf Half Y5.11%
Book/sh40.59 P/B4.06 EPS next Y3.29% ROA10.10% Target Price185.23 Perf Year3.74%
Cash/sh51.75 P/C3.18 EPS next 5Y6.49% ROE25.90% 52W Range131.83 - 184.21 Perf YTD13.36%
Dividend4.60 P/FCF18.58 EPS past 5Y20.50% ROI13.00% 52W High-12.06% Beta1.28
Dividend %2.79% Quick Ratio3.90 Sales past 5Y8.10% Gross Margin81.90% 52W Low22.87% ATR2.14
Employees19200 Current Ratio4.10 Sales Q/Q7.70% Oper. Margin42.60% RSI (14)41.19 Volatility1.13% 1.15%
OptionableYes Debt/Eq1.16 EPS Q/Q10.50% Profit Margin33.60% Rel Volume2.34 Prev Close164.61
ShortableYes LT Debt/Eq1.01 EarningsApr 26 AMC Payout38.70% Avg Volume3.79M Price161.99
Recom2.40 SMA20-0.55% SMA50-4.47% SMA2000.78% Volume1,934,175 Change-1.59%
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-27-17 10:33AM  NICE Recommends Amgen's BLINCYTO® (Blinatumomab) for Adults With Relapsed or Refractory Philadelphia Chromosome-Negative B-Precursor Acute Lymphoblastic Leukaemia PR Newswire
09:21AM  Amgen's Q1 Results Highlight the Need for an Acquisition Motley Fool
09:18AM  AbbVie Nears Buy Point As Earnings, Sales Top Investor's Business Daily
07:55AM  Celgene Earnings Top, But Biotech's Sales Miss Investor's Business Daily
07:47AM  Early movers: CMCSA, LUV, F, DOW, RTN, BMY & more CNBC
Apr-26-17 08:23PM  Amgen Reports Mixed Financials Results as Its Lead Drug, Enbrel, Sees Sales Decrease TheStreet.com
07:02PM  Amgen Reports Mixed Financials Results as Its Lead Drug, Embrel, Sees Sales Decrease TheStreet.com
07:00PM  Evening Movers: Amgen Slumps, Weight Watchers Jumps, Las Vegas Sands Slips Barrons.com
06:35PM  Cost controls help offset lower Amgen first-quarter drug sales Reuters
05:41PM  Amgen CEO: Hopeful Trump administration can deliver tax r... CNBC Videos
05:36PM  After-hours buzz: PYPL, AMGN, FFIV & more CNBC
05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
04:24PM  Amgen tops 1Q profit forecasts Associated Press
04:21PM  Amgen shares slide on weak Enbrel sales MarketWatch
04:10PM  Amgen first-quarter profit exceeds Street estimates on lower costs Reuters
04:08PM  New Cholesterol Drug Falls Short as Sales Driver for Amgen Bloomberg
04:05PM  Amgen EPS beats, revenues miss CNBC Videos
04:01PM  Amgen Reports First Quarter 2017 Financial Results PR Newswire
02:19PM  U.S. top court grapples over making copycat biologics available sooner Reuters
01:35PM  Will Amgen's Rivals Pop On Its Cholesterol-Busting Drug? Investor's Business Daily
12:23PM  U.S. top court debates making copycat biologics available sooner Reuters
12:14PM  Time for Big Cap Biotech Investopedia
09:40AM  Short Sellers Grow More Selective on Major Biotechs 24/7 Wall St.
08:18AM  Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug Zacks
07:20AM  Better Buy: Amgen Inc. vs. Biogen Motley Fool
Apr-25-17 07:08PM  Martin Whitman Sells Comerica, Buys Amgen GuruFocus.com
04:22PM  Amgen likely aiming to meet, not beat, first-quarter earnings expectations MarketWatch
03:46PM  Novartis, Amgen Divvy Global Marketing of New Migraine Drug TheStreet.com
08:43AM  3 Stocks Could Double Their Dividends -- But Shouldn't Motley Fool
08:39AM  Why Earnings Season Could Be Great for Amgen (AMGN) Zacks
08:26AM  Earnings Preview: What To Expect From Amgen On Wednesday Forbes
06:50AM  Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Zacks
Apr-24-17 04:30PM  Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine PR Newswire
02:49PM  Biotech: 3 Things to Focus on as Biogen and Amgen Report Barrons.com
10:06AM  Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1? Zacks
08:42AM  Better Buy: Amgen Inc. vs. Pfizer Motley Fool
Apr-23-17 06:55PM  Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector TheStreet.com
02:03PM  Read This Before You Buy Biotech Stocks Motley Fool
10:25AM  Alphabet, Amazon, AT&T and Other Key Earnings Coming This Week 24/7 Wall St.
Apr-21-17 04:15PM  Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Investor's Business Daily
04:00PM  Amgen Announces Webcast Of 2017 First Quarter Financial Results PR Newswire
11:18AM  Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again? Zacks
Apr-20-17 05:53PM  What to expect from biotech CNBC Videos
02:55PM  Celgene to expand in Cambridge, taking former Amgen space American City Business Journals
10:16AM  What's in Store for Biogen (BIIB) this Earnings Season? Zacks
09:31AM  Sanofi Genzyme hit with patent lawsuit over new eczema drug American City Business Journals
Apr-19-17 04:17PM  Is J&J's Pharma Sales Slowdown a Warning for Other Players? Zacks
Apr-18-17 04:00PM  Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Alphabet, Amgen, Lowe's, Bristol-Myers and Priceline Zacks
Apr-17-17 05:43PM  Billion dollar drug bust CNBC Videos
04:43PM  Top Research Reports for Alphabet, Amgen & Lowe's Zacks
01:03PM  5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates Zacks
Apr-15-17 12:23AM  [$$] As Drug Prices Fall, These Stocks Could Rise Barrons.com
Apr-13-17 04:18PM  The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Barrons.com
Apr-12-17 03:46PM  Amgen's Offering a Money Back Guarantee for Repatha. Will It Be Enough? Motley Fool
12:51PM  How These Biotechs Could Save The Drug Sector In Q1 Or Not Investor's Business Daily
10:13AM  Don't Get Your Hopes Up For Biotech's Q1 Earnings Barrons.com
09:10AM  Short Sellers Back Off Major Biotechs 24/7 Wall St.
06:00AM  First Quarter Earnings Preview: Biotech Heavyweights Investopedia
Apr-11-17 03:03PM  3 Big Drugmakers Most Likely to Buy Incyte Motley Fool
08:08AM  The 3 Top Dividend Stocks in the Healthcare Sector Motley Fool
Apr-10-17 09:49AM  10 Reasons Amgen Could Be the World's Most Perfect Stock Motley Fool
03:40AM  Why Big Pharma Is Turning to Biological Drugs MarketWatch
Apr-09-17 04:16PM  Amgen Files Marketing Applications to Expand Xgeva's Use to US and EU MM Paitents GuruFocus.com
Apr-08-17 04:11PM  3 Big Biotech Stocks With Big-Time Catalysts Motley Fool
Apr-07-17 02:00PM  Earnings Preview: Biotechnology Looks Healthy Barrons.com
01:38PM  Analysts Release New Health Care Stock Ratings GuruFocus.com
01:34PM  Why Roche's New Drug Is Bad News For Biogen Barrons.com
Apr-06-17 03:31PM  Iceland's genetic goldmine, and the man behind it CNBC
03:30PM  Iceland: Genealogists' heaven CNBC Videos
01:08PM  Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy Benzinga
08:03AM  This Is Why Radius Health Inc. Tumbled 8.6% in March Motley Fool
Apr-05-17 04:21PM  Amgen Payer Pushback Likely To Sting Amid Battle With Regeneron, Sanofi Investor's Business Daily
04:20PM  Citigroup, Wells Fargo Upgraded; Tenet A Buy; Teradyne PT Hiked Investor's Business Daily
12:06PM  Amgen Receives Hold Rating at Jefferies -- Jim Cramer Says It Could Be a Battleground TheStreet.com
11:20AM  Amgen Files for Xgeva Label Expansion, To Include Myeloma Zacks
09:53AM  Cramer's Stop Trading: Amgen downgrade CNBC Videos
08:59AM  Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug Zacks
04:00AM  Why Is Amgen (AMGN) Up 12.9% Since the Last Earnings Report? Zacks
Apr-04-17 11:12AM  As Biotech Roars Back, Amgen Remains Dirt Cheap TheStreet.com
09:22AM  What's Next for Amgen's Repatha? Motley Fool
09:00AM  Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma PR Newswire
08:03AM  The No. 1 Dividend Grower For 2017 (From 50 Elite Finalists)
08:03AM  Amgen Offers A Money-Back Guarantee For Its Cholesterol Drug Repatha
Apr-03-17 03:10PM  Amgen will move 100 workers to San Francisco, Cambridge as part of restructuring at bizjournals.com
11:00AM  Sarepta chief hands over CMO role to former Regeneron exec at bizjournals.com
07:06AM  Kite Pharma Completes Filing for CAR-T Therapy with FDA
Apr-02-17 03:02PM  Healthcare Winners and Losers Following the AHCA's Failure at Motley Fool
Apr-01-17 11:42AM  Better Buy: Celgene Corporation vs. Amgen Inc. at Motley Fool
11:30AM  Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) PR Newswire
Mar-31-17 03:36PM  FDA Grants Amgen Priority Review for Blincyto sBLA
10:36AM  Novartis Expects to Launch 5 Key Biosimilars by 2020
09:43AM  Can Vertex Keep Climbing? at Barrons.com
09:00AM  Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting PR Newswire
Mar-30-17 04:20PM  The 3 Best Cholesterol Drug Stocks to Buy in 2017 at Motley Fool
09:46AM  Amgen's Leukemia Drug Accepted for Priority Review by FDA
09:46AM  Amgen's Leukemia Drug Accepted for Priority Review by FDA at Investopedia
09:22AM  Amgen's Blincyto sBLA Secures FDA Priority Review at Investopedia
06:00AM  7 Dividends That Have Doubled Quickly at Motley Fool
Mar-29-17 04:07PM  FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application PR Newswire
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM